achieving this Thank medicines call, the we you for you, ago, afternoon. goal, year-end FDA. our X of of a year to that on meeting the all following of Pete, Phase cancer. committed talked At another treatment promise joining and we're for us Kura, successful precision toward step with thank realizing of end Approximately taking one
way. in pleased cell neck HRAS-mutant directed year our of I'm carcinomas tipifarnib registration squamous very a that and report later, Now is under to head trial
for potential T-cell association or solid over broaden expand us of the past PTCL, cancer. the AITL, year showed angioimmunoblastic these tipifarnib also considerable enrich in helping with and for demonstrated clinical benefit clinical addition lymphoma made the our lymphoma in patients opportunity we've T-cell solid activity in HRAS-mutant In or pancreatic indications, target tumors, peripheral potential clinical beyond in and to between validated treat CXCLXX We multiple the CXCLXX to as efforts identified Together, tipifarnib are proof-of-concept tipifarnib. well HRAS-mutant how tumors. a to to expression efforts in to strides therapeutic
we ahead, Now each directed registration remains Phase of look to the top the our date in of as our forward X three from ongoing of trials priority. year our clinical execution tipifarnib, trial
which with control As we a cohort, a tipifarnib determine trial registration-directed reminder, our is outcomes call as of rate treatment we a designed of HNSCC with case cohorts; carry cohort metastatic and HRAS outcome first-line determine objective SEQ-HN SEQ-HN of HRAS-mutant primary of screening to call HNSCC without to which two compared the and a in AIM-HN. known mutations SEQ-HN, treatment has HRAS mutations. those patients the patients HRAS-mutation. is that a therapy to The HNSCC objective non-interventional in recurrent or study with response
patients with years XX% XX% The power platinum-based the for to enable for AIM-HN XX of has who recurrent the addition, detect received endpoint of patients AIM-HN to therapy screening HRAS-mutant expected is mutations is point of cohort enroll. null considered trial's HNSCC metastatic into rate with interest. AIM-HN approximately objective a HRAS is and rate. enroll at two which objective November second-line and in year last prior is of expected designed AIM-HN. the to of primary hypothesis XX%, an to response difference between potential fully objective is initiated and therapy. of a to In rate take response estimate and the disease identification response approximately enrollment outcomes least have
from trial, reject the of HRAS-mutant FDA, the second it confirmed AIM-HN. XXXX, we such cancers, of patients the trial RUN-HN based update X in in follow-up ongoing as drug an the on including as in-licensed However, as both feedback observed which will RUN-HN and We to responses our are in more include from other observed, regarding as information cancers. this newly in as a HNSCC patients leukemias, tipifarnib maybe support AIM-HN order hypothesis. lymphomas registration at our ongoing provide the assumptions, new open pancreatic from could as continue to providing Janssen soon that of that XX data application plan preliminary adequate directed trial on believe enroll upon yet if HNSCC to positive, we statistical SCC patients Based half features expect positive to We be to update reports call compelling when and accelerated in the on at trial, anecdotal certain enrolled anticipate in our well anti-tumor program, meeting. as clinical tumors breast and and solid Among where we an we seeking have activity of Phase approval. design sites various Meanwhile, upcoming we cohorts. medical null the across the well
pharma had we decade, carry activity be that inhibition of inhibitor the worked the Despite not observed enzyme HRAS these than to fact do tumors on been a for hypothesize relate molecular farnesyltransferase in mechanism no anti-tumor might molecular Given patients. the a described. mechanism there programs that more multiple mutations, companies typically that such the would large farnesyltransferase
valuable Of between our ongoing December a preliminary and levels clinical data in from XX%. reported The four concept also achieved showed trial, response two of proof have a association trial provided significant and form response objective AITL, benefit. of achieved rate XXXX, previously in expression. Our of recently the with by PTCL, CXCLXX a for the an an most partial response ASH aggressive of in patients complete expression clinical characterized PTCL a results in often XX AITL patients high CXCLXX at
particularly We the subset responsive X a Phase also in trial. identified patient
given of a response in patients benefit with of the with ratio to words, tipifarnib. its to expression ratio clinical and the of CXCLXX XX% Specifically, XX% rate a experienced XX receptor rate high trial, a expression, CXCRX a with patients of CXCLXX high of In other activity the CXCRX, objective progressed. standard-of-care patient negative the one that study prior level factor prognostic Results non-clinical were indicate a therapy. salvage three for high only median that patients noteworthy ancillary the setting, This of is in CXCLXX experienced particularly an PTCL of therapies. from having was clinical
Our target benefit data pursue suggests provide likely for treatment. express from results a as CXCLXX preliminary using related PTCL of our a ASH, the to validate CXCLXX observation that XX% patients potential tipifarnib enrich biomarkers high that path as We is and of the many the therapeutic to of pathway development tipifarnib believe most to reported CXCLXX. patients at
acute these biomarkers, including We're the in and patients patients and We for represents indications in presenting with AITL of data ongoing this we've CXCLXX medical with other the activity later potential We refractory utility extend may potential cohort Phase to of is encouraged observed data in untreated, of encouraging patients including by plays from elderly X lymphoma poor data upon clinical our additional in update CXCLXX or trial a indications. at pathway from also X use as our mid-XXXX. from enrichment We critical working trial, high PTCL additional cells. this patient chronic stratified anticipate the The levels biomarkers, another an relapsed, myelomonocytic late-line leukemia CMML signs in ongoing meeting myeloid or leukemia settings, and growth CXCLXX trial in previously of cohort myeloid our CMML allow anticipate and response to roles mediating approach lymphoid homing Phase AML. year. duration the validate in a CXCLXX of pathway strategy risk myeloid myeloid tumor are Enrollment in this we CMML. providing us believe the and tipifarnib on pathway If based believe confirmed, opportunity. registrational of to data
the that tipifarnib evidence others, we've pathway, which our we pursued roles, tipifarnib the the we reported. presented fungoides cancer PTCL these being and that this CXCLXX indication We indications an certain are development Mycosis other are leaders identifying this pancreatic in and us Malignancies. known pancreatic of pancreatic in pancreatic are treated approach cancer. study as tipifarnib to the to currently in retrospective clinical that in solid on expression development findings Hematologic CDXX and in has findings trials CXCLXX receptors as to contribute ASCO activity with other known they Such modulation we key a expression including at CXCLXX also Hematologic form Malignancies of our elevated furthermore, investigate encouraged to and across T-cell approach update by year. currently acting this analysis investigators and such lymphoma many tipifarnib. may made in tumors CMML, association patients role factor multiple to January and been large lymphoma expect between of be believe metastasis, AML populations We're guided Lymphoma, Janssens CXCLXX of area Hodgkin's is diseases notion design us diffuse in The an and a trials progress its In opinion B-Cell support in of a pursue in provide with unselected targets XXXX, and cancer. already as patients across CXCLXX through to in benefit support potential proof-of-concept is with its including with is the an against further motivated these a of plans a relevant believe CXCLXX on We of our Poor successfully Prognosis cutaneous GI ongoing working biomarker allow later of new guided Among a and to expressing biomarker well has cancer.
working in that for our patients, action enrolling and we this it's Hematologic currently deprioritized tipifarnib X resources we've new our and actively in tumor Although is to other Meanwhile, of of opportunity study has we Phase farnesyl pathway tipifarnib. redirect significant and of of specific may In CXCLXX biology we indications. Malignancies, solid toward CXCLXX prioritize see elucidate molecular regard been tipifarnib those transferase many our mechanisms myelodysplastic also effort not the so in the further mediated syndromes that important been a efforts.
and R&D well toward of has between farnesylated as as made inhibition linkage mechanistic protein identification transferase Our CXCLXX. targets team farnesyl potential progress the the
ex-US tipifarnib genetically year. in related development indications, progress and commercial have certain topics part AITL protection We XXXX. to meetings these to In year. an generate program the made we've US on in and pleased say tipifarnib patient This intellectual include use disease and to tipifarnib more continuing the to cancers, US medical strategy to populations We've the is our summary, patent. expanded past with our the property we're also exclusivity CXCLXX of of additional pursue expect patent defined providing very over to this in I'm expressing for at important and to
insights in continue the have utility active why clinical of and of how excited better as tipifarnib, clinical explore we to a We potential into to tipifarnib enrich clinical better and understanding We're is to on these settings registration-directed execute our trial. for different broaden activity. opportunities
our attention that have potent a let's is KO-XXX a Now, activity dysregulated which our in treatment two pathway. the turn kinase, and selective mitogen-activated or extracellular are inhibitor programs. to potential emerging kinase for protein ERK of quickly patients advancing signal-related inhibitor KO-XXX. pipeline we molecule as tumors Beginning our MAPK with small with
anti-tumor certain carcinomas. Our subsets squamous BRAF-mutant suggests cell has KO-XXX well adenocarcinomas, activity preclinical data as or in as that KRAS of
evaluate and data from Phase X for KO-XXX, to a continue We anticipate having in and doses trial we our schedules of XXXX. number
or full application, as to molecule discussion report oncogenic KO-XXX, AML a duplication acute leukemia results quarter. protein-protein activity inhibitor a initiating those of our X or the the that, pleased and Marc defined KO-XXX subset the anticipate trial is clinical next IND of financial has for potent generated and as that call quarter genetically of in gene, candidate in FDA mutations product I'm of including well cleared preclinical support small data the in genes the partial relapsed our We've leukemia I'll XXXX. those menin-MLL, such of Grasso menin-mixed selective anti-tumor over Phase potential KO-XXX With third interaction. tandem with for rearrangements lineage MLL the with driver Our year NPMX. we our fourth refractory to of or turn and now as
